OCR Document - Research



June 2017

CURRICULUM VITAE

Hyun S. Kim, M.D.

San Diego Digestive Disease Consultants, Inc.

Medical Associates Research Group, Inc.

Diplomate American Board of Gastroenterology

Board Certified

8008 Frost Street 15611 Pomerado Road

Suite 200 Suite 500

San Diego, CA 92123 Poway, CA 92064

(858) 292-7527 24-Hour (858) 277-5678 MARG (858) 487-2121

(858) 292-7804 SDDD Fax (858) 277-2317 MARG Fax (858) 487-3321 Fax

EDUCATION:

1985 A.B. University of California, Berkeley, California

1990 M.D. Albany Medical College, Albany, New York

POSTDOCTORAL TRAINING:

1990-1991 Internship in Internal Medicine,

Boston City Hospital, Boston Univ. School of Medicine, Boston, MA

1991-1993 Residency in Internal Medicine,

Boston City Hospital, Boston Univ. School of Medicine, Boston, MA

1993-1994 Clinical Fellow in Medicine, Gastroenterology,

Brigham and Women's Hospital, Harvard Medical Sch., Boston, MA

1994-1996 Research Fellow in Medicine, Gastroenterology,

Brigham and Women's Hospital, Harvard Medical Sch., Boston, MA

1998. Senior Research Fellow in Medicine, Gastroenterology,

Brigham and Women's Hospital, Harvard Medical Sch., Boston, MA

. LICENSURE AND CERTIFICATION: CA License: G85388

1991 . Diplomate, National Board of Medical Examiners

1992-1999 Massachusetts License Registration .

1995 Diplomate, American Board of Internal Medicine

1997 Diplomate, American Board of Internal Medicine, Gastroenterology

1999- California License Registration

2009 Good Clinical Practice Certificate – Sponsor

2014 Good Clinical Practice Course – CITI

2016 Good Clinical Practice Course – CITI

ACADEMIC APPOINTMENTS:

1985-1986 Research Assistant University of California, Berkeley

1991-1993 Teaching Fellow in Medicine Boston University School of Medicine

1996-1998 Senior Research Fellow in Medicine Brigham and Women's Hospital

1998-1999 Instructor in Medicine Harvard Medical School

Brigham and Women's Hospital

1999-2001 Assistant Adj. Professor of Medicine University of California, San Diego

2001 Assistant Professor in Residence University of California, San Diego

HOSPITAL APPOINTMENTS:

1993-1998 Fellow in Medicine/GI Brigham and Women's Hospital

1998-1999 Associate Physician Brigham and Women's Hospital

1999-pres. Staff Physician UCSD Medical Center and

1999-pres. Staff Physician San Diego VA Medical Center

EMPLOYMENT: San Diego Digestive Disease Consultants

San Diego, California

2005-Present

Medical Associates Research Group, Inc.

San Diego, California

2005-Present

San Diego Endoscopy Center

4033 Third Ave., San Diego, California

2005-present

AWARDS AND HONORS:

1985 Honors Graduate, University of California, Berkeley

1998 Oncology Summer Research Fellowship

1996-1998 Individual National Research Service Award, U.S. Public Health Service

American Digestive Health Foundation Training Award

Crohn's and Colitis Foundation of America Fellowship Award

1998-2003 Mentored Clinical Scientist Development Award, NIDDK/NIH

1999-2000 UCSD Academic Senate Research Grant '.

2000-2001 UCSD Medical Education Research Foundation Scholars Program Research Grant

2003-2004 American Gastroenterological Association/Miles Fiterman Research Award

2004-2005 UCSD Academic Senate Research Award

MAJOR COMMITTEE ASSIGNMENTS:

1996-1998 Harvard Digestive Diseases Center Postdoctoral/Junior Faculty Seminar Committee Member, Brigham and Women's Hospital

1996-1999 Harvard Digestive Diseases Center, Associate Member

1998-1999 Joint Committee on the Status of Women, Harvard Medical School, Member 2002- Academic Senate Research Committee Member, UCSD School of Medicine

MEMBERSHIPS, OFFICES, AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

1990-1992 Sigma Xi member

1988- American College of Physicians, Associate member

1990- Massachusetts Medical Society

1993- American Gastroenterological Association

1993- American College of Gastroenterology

1994-1996 American Association for the Study of Liver Diseases

1999- San Diego Gastroenterology Society member

2002- Crohn’s' and Colitis Foundation of America, member

2003- San Diego Medical Society, member

OTHER CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES:

1992-1997 East Boston Neighborhood Health Care Center, Urgent care physician, Boston, MA

1995-1996 Fernald State School, Gastroenterology consultant. Boston, MA

1995-1996 Wrenthain State School, Gastroenterology consultant. Boston, MA

1996-1999 Harvard Vanguard Health Center, Gastroenterology consultant. Boston, MA

1996-1999 New England Shelter for the Homeless Veterans Clinic, Attending physician. Boston, MA

2001- Attending, Total Parenteral Nutrition Service, San Diego VA Medical Center

2002- Coordinator, UCSD Division of Gastroenterology, Journal Club

2002- UCSD School of Medicine 208, Human Diseases Course, Coordinator for Gastroenterology

Section

REPORT OF RESEARCH:

Major Basic Research Interests:

.

1. Function of CD 1 d in mucosal immune system and in infection.

2. Immune modulators in colitis-associated colon cancer

3. Gastroenterology immune recovery and reconstitution after therapy in IBD

Major Clinical Research Interest:

2001 - 2002 Principal Investigator

a4β37 Antibody Phase II clinical trial for Ulcerative Colitis

2002- Co-Principal Investigator

Immune.ablation and hematopoietic stem cell support in patients with severe Crohn's disease (Co-PI, Dr. Ewa Carrier)

2003- Co- Principal Investigator

Humanized TNF-a therapy for Crohn's Disease (Co-PI, Dr. Arthur Kavanaugh)

Masser C, Paesold G, Eckmmm L, Kim HS, KagnoffM. Ubiquitous production of macrophage migration inhibitory factor by human gastric and intestinal epithelium. Gastroenterology. 2002; 122:667-680.

Arrunategui-Correa V, Kim HS. The role of CD 1 d in the immune response against Listeria infection. Cellular Immunology. 2004;227: 109-120. .

Arrunategui-Correa V, Weinstock J, Kim HS. Development of colitis and activation of immune system after piroxicam treatment in IL-l 0 deficient mice. Manuscript in preparation.

Arrunategui-Correa V, Kim HS. Mechanism of cellular inflammatory immune response during Listeria monocytogenes infection - Role of CD 1 d and NKT cells. Manuscript in preparation.

Arrunategui-Correa V, Kim HS. Induction of KLRG 1 on NKT cells following Listeria monocytogenes infection- Manuscript in preparation.

Book Chapters

Blumberg R, Probert C, Christ A, Kim HS, Polischuk J, Morales V, Gerdes-D, Chott A, Balk S. The role of epithelial cells. Inflammatory Bowel Diseases, Falk Symposium No. 85, Kluwer Academic Publishers, 1995: 266-274.

Blumberg RS, Colgan SP, Morales V, Kim HS, Balk SP. Non-classical MHC class I molecules on human intestinal epithelial cells and their role in IEL function. In: Antigen Presentation by Intestinal Epithelial Cells, Dominique Kaiserlian, (eds), R.G. Landes Co, 1996, pp. 77-95.

Kim HS, Blumberg RS. T-cell selection and epithelialligands in the Gastroenterology tract. In: The Immunobiology of H pylori from Pathogenesis to Prevention, Peter Ernst, Pierre Michetti, Phillip D. Smith, (eds), Lippincott Raven, New York, 1997, pp. 138-152.

Kim HS, Blumberg RS. Major histocompatibility complex class I-related molecules in intestinal immunobiology. In: Bioregulation and its Disorders in the Gastroenterology Tract, Yoshikawa H, (eds), Blackwell Science Publishers, Tokyo, 1998, pp. 291-301.

Kim HS. 3 Chapters: "Lymphoma," "Mucosa-associated lymphoid tissue (MALT)," "Mycobacteria," In: Encyclopedia of Gastroenterology, LR Johnson (eds), Elsevier Academic Press. 2003

Reviews

Kim HS, Christ A, Colgan S, Somnay-Wadgoankar K, Balk SP, Blumberg RS. Role of CD 1 in intestinal immune function. Mucosal Immunol. Update. 1997;5:25-29.

Blumberg RS, Lencer WI, Zhu ZP, Kim HS, Claypool S, Balk SP, Saubermam1 LJ, Colgan SP. Antigen presentation by intestinal epithelial cells. Immunol. Letters 1999;69:7-11.

Kim HS. Prevention of Colon Cancer with Ursodiol in Ulcerative Colitis. Inflammatory Bowel Disease. 2001;7:279-280.

Abstracts

Kim HS, Polischuk J, Balk SP, Blumberg RS. Development and characterization of a CDld model system in a_2-microglobulin-negative cell line. Gastroenterology 1996; 11 0:A93 7.

Kim HS, Rogers SA, Liang TJ, Blumberg RS. Identifying eDld interacting proteins by yeast two-hybrid system. Gastroenterology 1997;112:AI012.

Kim HS, Hershberg R, Balk SP, Blumberg RS. Characterization of CDld biosynthetic pathway in a transfected T84 cell line. Gastroenterology 1998: 114:A836.

Kim HS, Hershberg R, Colgan S, Blumberg RS. Hydroxylation of proline residues in CDld. Gastroenterology 1999;116:A748.

Kim HS, Garcia J, Exley M, Johnson K, Balk SP, Blumberg RS. Biochemical characterization of CDld in transfected FO-I cell line. Gastroenterology 1999;116:A748.

Kim HS, Pitman R, Bershberg R, Colgan S, Balk SP, Blumberg RS. Hydroxylation of proline residues in CDld. Keystone Symposium "Innate and Acquired Immunity at Mucosal Surfaces," Taos, New Mexico, January 2000.

Han SH, Kim HS. Protection against Listeria infection in CDI KO mice is mediated by Thl cytokine response. Keystone Symposium "Microbial-Epithelial-Lymphocyte Interactions in Mucosal Immunity," Breckenridge, CO, ApriIS-IO, 2002.

Han SH, Kim HS. Protection against Listeria infection in CD I KO mice is mediated by Thl cytokine response. Gastroenterology 2002;122:A273.

Arrunategui-Correa V, Kim HS. CDld-dependent differential TLR expression in mucosal tissues during oral Listeria monocytogenes infection. Gastroenterology. 2Q04;126:A570.

Arrunategui-Correa V, Weinstock J, Kim HS. Phenotypic analysis for NKT, NK, and T cells in an NSAID-induced model of colitis in IL-IO KO mice. Gastroenterology. 2004;126:A421.

Arrunategui-Correa V, Kim HS. Induction of expression ofKLRG1.on NKT cells and conventional CD4+ and CD8a+ T cells in non-lymphoid tissues after oral Listeria monocytegenes infection. Gastroenterology. 2004;126:A294.

CLINICAL RESEARCH:

1. Randomized, Double-Blind, Double-Dummy, Placebo-Controlled 26-week Dose Response study of XXXX with Active Comparator in Subjects with Type 2 Diabetes. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. Sankyo Pharma Development. (Medpace).

2. A Randomized, Double-Blind, Controlled Evaluation of XXXX for the Treatment of Presumed Pre-core Mutant Chronic Hepatitis B. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. Gilead Sciences.

3. A Randomized, Double-Blind, Controlled Evaluation of XXXX for the Treatment of HbeAg Positive Chronic Hepatitis B. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. Gilead Sciences.

4. A 12-Week, Multicenter, Double-Blind, Randomized, Efficacy and Safety Study of XXXX for the Treatment of Constipation-Predominant Irritable Bowel Syndrome. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. Sucampo Pharmaceuticals (PRA).

5. A Double-Blind Randomized Study to Evaluate the Efficacy and Safety of XXXX vs Placebo in Subjects with Primary Hypercholesterolemia. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. Takeda Global Research and Development, Inc. (PPD).

6. An Open-Label Extension Study to Evaluate the Safety and Tolerability of XXXX in Subjects with Hypercholesterolemia. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. Takeda Global Research and Development, Inc. (PPD).

7. A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, XXXX, for the Induction of Clinical Response in Patients with Crohn's Disease. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. Synta Pharmaceutical Corp. (PPD).

8. Determination of the Minimal Clinically Important Difference (MCID) of the patient-orientated self assessment scale ReQuest™ in patients suffering from endoscopically confirmed gastroesophageal reflux disease (GERD), Grade A-D according to Los Angeles classification treated with pantoprazole 40mg o.d. or placebo o.d. over one week. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. ALTANA Pharma AG.

9. A Phase 3 Study to Evaluate the Efficacy and Safety of XXXX (60 mg QD and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects with Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. TAP Pharmaceutical Products, Inc.

10. A Phase 3 Study to Evaluate the Efficacy and Safety of XXXX (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. TAP Pharmaceutical Products, Inc.

11. A Phase 3 Study to Evaluate the Safety and Efficacy of XXXX (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. TAP Pharmaceutical Products, Inc.

12. A Phase 3, Open-Label Study to Assess the Long-Term Safety of XXXX (60 mg QD and 90 mg QD). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. TAP Pharmaceutical Products, Inc.

13. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of XXXX in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. Alizyme Therapeutics Limited (Quintiles).

14. A Phase III, Multicenter, Open Label, Extension Study to Evaluate the Long-Term Safety of Renzapride 4 mg Once Daily in Women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2005. Alizyme Therapeutics Limited (Quintiles).

15. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Different Doses of XXXX Administered BID For Either Two or Four Weeks in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2006. Salix Pharmaceuticals, Inc. (Kendle).

16. A Phase 2a, Randomized, Double-Blind, Placebo Controlled Dose Ranging, Multi-Center Study to Determine the Safety, Tolerance, and Efficacy of XXXX in Celiac Disease Subjects during Gluten Challenge. Principal Investigator Jeffrey Pressman, MD; Sub-investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2006. Alba Therapeutics.

17. Access® Immunoassay Systems Soluble Transferrin Receptor (sTfR) Assay Clinical Utility and Method Comparison. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2006. Beckman Coulter Inc.

18. A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Range-Finding, Parallel-Group Phase 2 Trial of XXXX Administered to Patients with Chronic Constipation. Principal Investigator Michael Bennett, M.D; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2006. Microbia (ICON).

19. A Multi-Center, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Flexible-Dose Study to Assess the Efficacy and Safety of XXXX in Men with Erectile Dysfunction (ED) who do not Self Identify. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2006. Pfizer (PPD).

20. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXXX for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS) in Females. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2006. Trine (ICON).

21. A randomized, double-blind, parallel-group study of cardiovascular safety in OA or RA patients with or at high risk for cardiovascular disease comparing celecoxib with naproxen and ibuprofen. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2006. Cleveland Clinic. Pfizer (Quintiles).

22. A Phase-2, Randomized, Open-Label Study of the Safety, Antiviral Activity, and Pharmacokinetics of XXXX Administered in Combination with Peginterferon Alfa 2B (Peg-Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol in Subjects with Hepatitis C Virus Genotype 1 Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2006. Wyeth Research (ICON).

23. A World-wide, Multi-Center, Double-Blind, Parallel Study to Evaluate the Tolerability of XXXX versus Niacin Extended Release. Principal Investigator Jeffrey Pressman, MD; Sub-Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD Medical Associates Research Group, Inc. 2006. Merck.

24. A Multi-Center Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of XXXX and Simvastatin Combination Therapy to XXXX and Simvastatin Monotherapy in Subjects with Mixed Dyslipidemia. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2006. Abbott Laboratories (Covance).

25. A Long-Term, Open-Label, Safety Extension Study of the Combination of XXXX and Statin Therapy for Subjects with Mixed Dyslipidemia. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2006. Abbott Laboratories (Covance).

26. A Multi-Center, Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of XXXX given twice daily for 4 weeks for the Relief of Irritable Bowel Syndrome (IBS) pain. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD Medical Associates Research Group, Inc. 2007. Allergan.

. 27. Multicenter, Randomized, Double-Blind Study, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of XXXX Versus Atorvastatin in Patients with Mixed Hyperlipidemia. Principal Investigator Jeffrey Pressman, MD; Sub-Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2007. Merck.

28. A Phase-3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of XXXX in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2007. Human Genome Sciences, Inc. (Duke Clinical Research Institute).

29. A 6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either XXXX or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2007. POZEN Pharmaceutical, Inc. (Premier Research).

30. A 6-Month, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study to Evaluate the Incidence of Gastric Ulcers with XXXX versus diclofenac/misoprostol in Subjects Who Are at High Risk for Developing NSAID-associated Ulcers. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2007. POZEN Pharmaceutical, Inc. (Premier Research).

31. A 12-Month, Phase 3, Open-Label, Multi-center Study to Evaluate the Long-term Safety of XXXX in Subjects Who Are at Risk for Developing NSAID-associated Ulcers. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2007. POZEN Pharmaceutical, Inc. (Premier Research).

32. A Double-Blind, Randomized, Placebo-Controlled Phase 2b Study of XXXX in Female Outpatients with Irritable Bowel Syndrome. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2007. Pharmos Corporation (ICON).

33. A Multi-center, Randomized, Double-Blind, Active-Control, 96-Week, Phase III Trial of the Efficacy and Safety of XXXX Compared with Adefovir in Nucleoside Treatment-Naïve Patients with HBeAg Positive Chronic Hepatitis due to Hepatitis B virus. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2007. Pharmasset, Inc. (PPD).

34. A Multi-center, Randomized, Double-Blind, Active-Control, 96-Week, Phase III Trial of the Efficacy and Safety of XXXX Compared with Adefovir in Nucleoside Treatment-Naïve Patients with HBeAg Negative Chronic Hepatitis due to Hepatitis B virus. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2007. Pharmasset, Inc. (PPD).

35. A Multi-center, Investigator-blinded, Randomized, 12-Month, Parallel-group, Non-inferiority Study to Compare the Efficacy of XXXX Therapy Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis. Principal Investigator Jeffrey Pressman, MD; Sub-investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2007. Procter and Gamble Company (UBS).

36. A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of XXXX Twice Daily vs. Placebo in Subjects with Hypercholesterolemia. Principal medication in the Morning vs. XXXX in the Evening vs. investigational Investigator, Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2007. Takeda Global Research and Development Center, Inc. (PPD).

37. A Randomized, Multi-center, Double-Blind, Placebo-Controlled, Dose-Range-Finding, Parallel-Design, Phase 2 Trial of XXXX Administered to Patients with Irritable Bowel Syndrome with Constipation. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2007. Microbia, Inc. (ICON).

38. A Multi-Center Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study of XXXX in Subjects with Symptomatic Gastroesophageal Reflux Disease (GERD) Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc., 2007. Xenoport (MDS).

39. A Phase-III, Randomized, Double-blind, Dose-Response Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of XXXX Versus Placebo over 104 Weeks in the Prevention of Recurrence of Diverticulitis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2008. Shire Pharmaceutical Development, Ltd. (Kendle).

40. A Double-blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of XXXX with Valsartan in Subjects with Essential Hypertension. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2008. Takeda Global Research and Development Center, Inc.

41. A Randomized Double-Blind Parallel Study of XXXX versus XXXX 40 mg for Healing and Symptomatic Relief of Erosive Gastroesophageal Reflux Disease (GERD). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2008. Eisai Medical Research Inc. and Johnson and Johnson Pharmaceutical Research & Development, LLC (PPD).

42. A Randomized Double-Blind Parallel Study of XXXX 50 mg vs. XXXX 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2008. Eisai Medical Research Inc. and Johnson and Johnson Pharmaceutical Research & Development, LLC (PPD).

43. A Randomized Double-Blind Parallel Study of XXXX 50 mg versus XXXX 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2008. Eisai Medical Research Inc. and Johnson and Johnson Pharmaceutical Research & Development, LLC (PPD).

44. A Phase 3 Study of 2 Dose Regimens of XXXX in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects with Genotype I Chronic Hepatitis C. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associate Research Group, Inc. 2008. Vertex (Parexel).

45. A Phase 3 Safety and Efficacy Study of XXXX in Subjects with Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment with Peginterferon/Ribavirin. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2008. Schering-Plough.

46. A Phase 3 Safety and Efficacy Study of XXXX in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2008. Schering-Plough.

47. An International, Multi Center, Randomized, Parallel Group, Prospective, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of a Combination Treatment Administered Over 3 Years in Patients at Risk of Experiencing Recurrence of Colorectal adenomas. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Colotech (PRS Clinical).

48. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of XXXX administered orally for 12 weeks Followed by a 4-Week Randomized Withdrawal Period in Patients with Chronic Constipation. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Ironwood Pharmaceuticals (ICON).

49. An Open-label, Long-term Safety Study of oral XXXX Administered to Patients with Chronic Constipation or Irritable Bowel Syndrome with Constipation. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Ironwood Pharmaceuticals (ICON).

50. A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered XXXX in Subjects with Non-Constipating Irritable Bowel Syndrome. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Lexicon Pharmaceuticals, Inc.

51. An 8-Week Randomized, Double-Blind, Parallel Group, Multi-Center, Forced Titration Study to Evaluate the Efficacy and Safety of XXXX plus HCTZ versus XXXX monotherapy in Metabolic Syndrome Patients with Stage 2 Hypertension. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Novartis.

52. A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C who Achieve an Extended Rapid Viral Response (eRVR) While Receiving XXXX, Peginterferon Alfa2a and Ribavirin. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Vertex (ICON).

53. A Single-Arm Study to Provide XXXX Treatment in Subjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough XXXX Studies. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009 Schering-Plough.

54. A Phase 3 Safety and Efficacy Study of XXXX in Combination with Peginterferon Alfa-2a and Ribavirin in Subjects with Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment with Peginterferon/Ribavirin. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Schering-Plough.

55. A Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging, Multi-Centre Study to Investigate the Efficacy, Safety, and Tolerability of the XXXX in Patients With Gastroesophageal Reflux Disease (GERD) Who Are Partial Responders to Proton Pump Inhibitor (PPI) Treatment. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Addex Pharma SA (SGS Life Science Services).

56. A Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of XXXX with XXXX in Subjects with Essential Hypertension, Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Takeda Global Research and Development.

57. A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety and Tolerability of XXXX 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (GERD). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Eisai Medical Research Inc. and Johnson and Johnson Pharmaceutical Research Inc. and Johnson and Johnson Pharmaceutical Research & Development, LLC (PPD).

58. An 8-Week, Multicenter, Randomized, Double-blind, Four-arm, Parallel-group Study Comparing the Safety and Efficacy of XXXX to Simvastatin in Subjects with Hypercholesterolemia. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Abbott Laboratories (Paragon Biomedical).

59. A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXXX in Subjects with Generalized Erectile Dysfunction. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Vivus, Inc. (Quintiles).

60. SELECT-2: Phase 2B, Partially-Blinded, Randomized Study in Treatment Naïve Subjects With HCV Genotype 1 To Compare The Efficacy, Safety, And Tolerability Of Three Doses Of LoctEron™ Plus Ribavirin Given Bi-weekly In Comparison With PEG-Intron™ Plus Ribavirin Given Weekly. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Biolex Therapeutics, Inc. SGS Life Sciences.

61. A Trial of XXXX in Interferon-Naïve Hepatitis C Patients. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Conatus Pharmaceuticals, Inc.

62. A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of XXXX in Adults with Chronic Hepatitis C Virus Infection. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Gilead Sciences, Inc. (PRA International).

63. Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of XXXX in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin). Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. GlaxoSmithKline.

64. Collection of Blood Samples for the Discovery of Biomarkers Associated with Irritable Bowel Syndrome. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Prometheus Therapeutics and Diagnostics.

65. A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor XXXX in Combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. F. Hoffman-La Roche, Ltd.

66. A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the XXXX Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2009. Takeda Global Research & Development Center, Inc.

67. A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of XXXX in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc., 2009. Takeda Global Research & Development Center, Inc.

68. A Double-Blind, Double-Dummy, Randomized, Active-Comparitor, Non-Inferiority Study of XXXX versus Naprosyn® for Twelve Weeks in Osteoarthritis Patients to Compare Endoscopic Gastric Ulcer Rates. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2010. Logical Therapeutics, Inc. (PRA International).

69. A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of XXXX in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2010. Tioga Pharmaceuticals, Inc. (RTI).

70. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXXX plus pegylated interferon alfa-2A and Ribavirin in Treatment Naïve HCV Genotype 1 Infected Subjects. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2010. Pfizer, Inc.

71. Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir was Administered for the Treatment of Chronic Hepatitis C. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2010. Schering Plough.

72. A Phase II double-blind, placebo-controlled study of two doses of XXXX in patients with NASH. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2010. Mochida Pharmaceutical Co. (MedPace).

73. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With XXXX, XXXX, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2010. Gilead Sciences (PRA).

74. A Phase 2b, Randomized, Double-Blind, Placebo Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of XXXX, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without XXXX Followed by Response Guided PEG and RBV in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2010. Gilead Sciences (PRA).

75. A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus infection. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Tibotec BVBA.

76. A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Conatus Pharmaceuticals, Inc.

77. Procurement of Blood Samples from IBD, GI Controls and Healthy Volunteer Subjects for Use in the Development of Gastrointestinal Disease Tests. Principal Investigator Michael T. Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Prometheus Laboratories.

78. A Randomized, Open-Label, Multi-Center Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of XXXX and/or XXXX with and without Ribavirin (RBV) for 8, 12 or 24 weeks in Treatment-Naïve and Null Responder Subjects with Genotype 1 Chronic Hepatitis C Virus Infection. Principal Investigator Michael Bennett, MD, Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Abbott Laboratories.

79. An Open-Label, Sequential Arm, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of XXXX with XXXX Dosed in Combination with XXXX with and without Ribavirin (RBV) in Treatment-Naïve Subjects with Genotype 1, 2, or 3 Chronic Hepatitis C Virus (HCV) Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Abbott Laboratories.

80. A Phase III, Randomized, Double-Blind and Placebo-Controlled Study of Once Daily XXXX 120 mg for 24 weeks and XXXX 240 mg for 12 weeks in Combination with Pegylated Interferon-a and Ribavirin in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Boehringer-Ingelheim (Quintiles).

81. Safety, Antiviral Effect and Pharmacokinetics of XXXX in Combination with XXXX and With or Without Ribavirin for 4, 16, 24, 28, or 40 weeks in Patients with Chronic HCV Genotype 1 Infection (Randomized Phase Ib/II). Principal Investigator Michael Bennett, MD, Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Boehringer-Ingelheim (Quintiles).

82. Open-Label, Single-Arm Evaluation of XXXX in Combination with Peg-Interferon Alfa-2A and Ribavirin in Black-African Americans, Latinos, and White-Caucasians with Chronic Hepatitis C Genotype 1 Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Bristol-Myers Squibb.

83. A Phase 3 Evaluation of XXXX Compared with XXXX in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naïve Patients with Chronic Hepatitis-C. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Bristol-Myers Squibb.

84. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Therapy using Combinations of Oral Antivirals (XXXXs) with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PRA International).

85. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with XXXX Alone or in Combination with XXXX with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PPD).

86. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy with XXXXs, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PPD).

87. A Phase-2, Randomized, Double-Blind, Placebo-Controlled Study of XXXX, and Ribavirin (RBV) Compared with XXXXs with XXXX or RBV in Treatment-Experienced Subjects with Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PPD).

88. A Phase-2, Randomized, Double-Blind, Placebo-Controlled Study of XXXXs and Ribavirin; XXXX and XXXX; XXXX and Ribavirin in Interferon Ineligible or Intolerant Subjects with Chronic Genotype 1a or 1b HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PPD).

89. A Phase 2b, Randomized, Double-Blind, Placebo Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of XXXX, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without XXXX Followed by Response Guided PEG and RBV in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PRA International).

90. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals XXXX with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Gilead Sciences, Inc. (PRA International).

91. A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of XXXX When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 Hepatitis C Virus Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Merck Research Laboratories.

92. A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of XXXX in Combination with Standard of Care in Hepatitis C Genotype 1 Treatment-Naïve Patients. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Novartis (Quintiles).

93. A Multi-Center, Open-Label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Oral Administration of XXXX in Combination with Pegylated Interferon and Ribavirin in Treatment-Naïve Patients with Chronic HCV Infection Genotype 1, 4, 5, or 6. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Pharmasset (Quintiles).

94. An International, Multi-Center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Regimens Containing XXXXs and Ribavirin in Patients with Chronic HCV Infection, Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Pharmasset (Quintiles).

95. A Phase 3, Multi-Center, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of XXXX and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients with Chronic Genotype 2 or 3 HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Pharmasset (Quintiles).

96. A Randomized, 12-Week Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Assess the Safety and Efficacy of XXXX in Patients with Chronic Idiopathic Constipation. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Synergy Pharmaceuticals, Inc. (Parexel).

97. An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of XXXX in Combination with XXXX with or without Ribavirin in Chronic Hepatitis C Genotype 1 Infected Prior Null Responders to Peginterferon/Ribavirin Therapy. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Tibotec BVBA.

98. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Intra-Anal Application of XXXX as a 0.5% Ointment in Subjects with Symptomatic Internal Hemorrhoids. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Ventrus Biosciences (inVentiv).

99. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXXX for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2011. Ardelyx, Inc. (ICON).

100. A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection (SVR Registry). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2012. Gilead Sciences, Inc. (PRA International).

101. A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection (Sequence Registry). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2012. Gilead Science, Inc. (PRA International).

102. A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV). Principal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2013. AbbVie.

103. A Long-Term Follow-up Study of Subjects Who Participated in A Clinical Trial in Which BMS-650032 and/or BMS 790052 Was Administered for the Treatment of Chronic Hepatitis C. Principal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2013. Bristol-Myers Squibb.

104. A Randomized Study to Evaluate the Safety and Efficacy of IDX719 in Combination with Simeprevir and Ribavirin for 12 Weeks in Subjects with Chronic Hepatitis C Infection. Principal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2013. Idenix Pharmaceuticals (Quintiles).

105. A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naïve Subjects with Chronic Genotype 1 HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2013. Gilead Sciences, Inc. (PRA International).

106. A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naïve Subjects with Chronic HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2013. Gilead Sciences, Inc. (Quintiles).

107. A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Experienced Subjects with Chronic HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2013. Gilead Sciences, Inc. (Quintiles).

108. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of AZD1722 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C). Principal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2013. Ardelyx, Inc.

109. A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C. Principal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2013. Bristol-Myers Squibb.

110. A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis. Principal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2013. Bristol-Myers Squibb.

111. A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects with Genotype 2 or 3 Chronic HCV Infection. Principal InvestigatorPrincipal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2013. Gilead Sciences, Inc.

112. A Phase II Clinical Trial to Evaluate the Efficacy and Safety of a Combination Regimen of MK-5172 with/without MK-8742 and/or Ribavirin (RBV) in Treatment-naïve Subjects with Chronic Hepatitis C Genotype 2, 4, 5 and 6 Infection. Principal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2013. Merck Sharp & Dohme Corp. (PPD).

113. A Phase 3 Evaluation of Daclatasvir and Sofosburiv in Treatment Naïve and Treatment Experienced Subjects with Genotype 3 Chronic Hepatitis C Infection. Principal Investigator Michael Bennett, MD; Sub-investigator: Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2014. Bristol-Myers Squibb.

114. A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve and –Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection Without Cirrhosis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2014. Janssen Research & Development.

115. A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination with Sofosbuvir in Treatment-Naïve or-Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2014. Janssen Research & Development.

116. A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with Pegylated Interferon and Ribavirin (P/R) with Chronic HCV GT1, GT4, GT5, and GT6 Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2014. Merck Sharp & Dohme Corp. (PPD).

117. An Open-Label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered with Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2014. AbbVie.

118. An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir with or without Ribavirin (RBV) in Treatment-Naïve Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, with Severe Renal Impairment or End-Stage Renal Disease (RUBY-I). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2014. AbbVie.

119. An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2014. AbbVie (Covance).

120. A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects with Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2014. AbbVie (Covance).

121. A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects with Chronic HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2014. Gilead Sciences, Inc. (PRA).

122. A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2014. Gilead Sciences, Inc. (PRA).

123. A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 24 Weeks in Subjects with Chronic Genotype 3 HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2014. Gilead Sciences, Inc. (PRA).

124. An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Gilead Sciences, Inc. (PRA).

125. A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Genotype 1 HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Gilead Sciences, Inc. (PRA).

126. A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects with Chronic Non-Genotype 1 HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Gilead Sciences, Inc. (PRA).

127. A Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection in Gilead Sponsored Trials. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Gilead Sciences, Inc. (Duke Clinical Research Institute).

128. A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Crohn’s Disease. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Gilead Sciences, Inc. (ICON).

129. A Long-term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK5172 in a Prior Clinical Trial. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Merck Sharp & Dohme Corp.

130. A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3 Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Merck Sharp & Dohme Corp.

131. A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Ribavirin in Adults with Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. AbbVie.

132. A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients with Knee Osteoarthritis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. AbbVie.

133. A Randomized, Double-Blind, Multicenter Study to Explore the Effect of GED-0301 on Endoscopic and Clinical Outcomes in Subjects with Active Crohn’s Disease. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Celgene (PPDI).

134. A Phase 2, Open-label, Multicenter Study to Explore the Efficacy and Safety of Mongersen (GED-0301) in Subjects with Active Ulcerative Colitis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Celgene (PPDI).

135. A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Gilead Sciences, Inc. (PRAHS).

136. A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subjects with Chronic HCV Infection. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Gilead Sciences, Inc. (PRAHS).

137. A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Intercept Pharmaceuticals, Inc.

138. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Receptos, Inc. (Quintiles).

139. A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2015. Receptos, Inc. (Quintiles).

140. A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic Genotype 3 HCV Infection and Cirrhosis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2016. Gilead Sciences, Inc. (PRAHS).

141. A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection Who Have Not Received an NS5A Inhibitor. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2016. Gilead Sciences, Inc. (PRAHS).

142. A Phase 2, Multi-Center, Open-Label Induction Trial with Extension Period to Assess Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients with Moderately to Severely Active Crohn’s Disease Receiving Oral RPC1063 as Induction Therapy. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2016. Receptos, Inc. (Quintiles).

143. A 12-Week, Randomized, Double Blind, Placebo-Controlled Study with a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2016. Ardelyx, Inc. (ICON).

144. Collection of Blood Specimens from Subjects Infected with Chronic Hepatitis C Treated with Regimens Containing Sofosbuvir. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2016. Roche Molecular Systems, Inc.

145. A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients with Symptomatic Gastroesophageal Reflux Disease Not Completely Responsive to Proton Pump Inhibitors. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2016. Ironwood Pharmaceuticals, Inc. (PPDI).

146. An Open Label Long-Term Safety Study of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2016. Ardelyx, Inc. (ICON).

147. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects with Nonalcoholic Steatohepatitis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2016. Gilead Sciences, Inc. (PRAHS).

148. A Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2016. Cara Therapeutics, Inc. (INC Research).

149. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn’s Disease. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2016. Celgene Corporation (Quintiles).

150. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2017. Gilead Sciences, Inc. (PRAHS).

151. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH). Principal Investigator Michael Bennett, MD; Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2017. Gilead Sciences, Inc. (PRAHS).

152. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH). Principal Investigator Michael Bennett, MD; Sub-investigator Hyun Sil Kim, MD, Medical Associates Research Group, Inc. 2017. Gilead Sciences, Inc. (PRAHS).

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download